MELBOURNE, Australia and INDIANAPOLIS, Feb. 20, 2026 (GLOBE NEWSWIRE) -- (ASX: TLX, NASDAQ: TLX, "Telix") today announces ...

"This is very accommodating to DTE," one environmental attorney said about the nondisclosure agreements allowing DTE Energy ...

Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic ...

Olanzapine long-acting injectable suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation 1If approved, TEV-'749 could help address a ...

PTC Therapeutics has withdrawn its New Drug Application resubmission for Translarna following feedback from the US Food and ...

There is no doubt that India faces multiplicity of Laws (at the Centre) passed over many years to take care of eventualities and events as they arise during the nation development.  The intent of ...

SUMMIT NDA for bezuclastinib in patients with NonAdvSM submitted in December 2025; APEX NDA submission for bezuclastinib in patients with AdvSM ...

Immunic raised funds to support Phase 3 clinical trials of vidofludimus calcium for MS and transition into a commercial-stage company.

Praxis Precision Medicines Inc. reports fourth-quarter and full-year 2025 results Thursday before the market opens, ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the year ended December ...

The FDA has accepted the new drug application (NDA) for tirabrutinib (ONO-4059), a highly selective, irreversible, second-generation Bruton tyrosine kinase (BTK) inhibitor developed for the treatment ...